No products in the cart.
Mouse Monoclonal Anti-p27 KIP1 antibody (STJ99255)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-p27 KIP1 antibody.
Check alternative names for the antibodyExpand
|AA408329 antibody|AI843786 antibody|Cdki1b antibody|CDKN 1B antibody|CDKN 4 antibody|CDKN1B antibody|CDKN4 antibody|CDN1B_HUMAN antibody|Cyclin Dependent Kinase Inhibitor 1B antibody|Cyclin dependent kinase inhibitor p27 antibody|Cyclin-dependent kinase inhibitor 1B (p27, Kip1) antibody|Cyclin-dependent kinase inhibitor 1B antibody|Cyclin-dependent kinase inhibitor p27 antibody|Cyclin-dependent kinase inhibitor p27 Kip1 antibody|KIP 1 antibody|KIP1 antibody|MEN1B antibody|MEN4 antibody|OTTHUMP00000195098 antibody|OTTHUMP00000195099 antibody|p27 antibody|p27 Kip1 antibody|P27-like cyclin-dependent kinase inhibitor antibody|p27Kip1 antibody|Anti-p27 KIP 1 antibody [Y236] (ab32034)
SCBT cat No: sc-393380|sc-528|sc-393305|sc-56338|sc-1641|sc-776|sc-527|sc-56454|sc-53906|sc-53871|sc-6359|sc-9962|
Anti-p27 KIP1 antibody
|Catalogue No.|| |
Anti-p27 KIP1 antibody detects endogenous levels of p27 Kip1 and does not cross-react with related proteins.
Purified recombinant human p27 Kip1 protein fragments expressed in E.coli.
|Recommended dilution|| |
WB 1:500-2000; ELISA 1:10000-20000
|Molecular weight|| |
Anti-p27 KIP1 antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Anti-p27 KIP1 antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
AA408329 antibody, AI843786 antibody, Cdki1b antibody, CDKN 1B antibody, CDKN 4 antibody, CDKN1B antibody, CDKN4 antibody, CDN1B_HUMAN antibody, Cyclin Dependent Kinase Inhibitor 1B antibody, Cyclin dependent kinase inhibitor p27 antibody, Cyclin-dependent kinase inhibitor 1B (p27, Kip1) antibody, Cyclin-dependent kinase inhibitor 1B antibody, Cyclin-dependent kinase inhibitor p27 antibody, Cyclin-dependent kinase inhibitor p27 Kip1 antibody, KIP 1 antibody, KIP1 antibody, MEN1B antibody, MEN4 antibody, OTTHUMP00000195098 antibody, OTTHUMP00000195099 antibody, p27 antibody, p27 Kip1 antibody, P27-like cyclin-dependent kinase inhibitor antibody, p27Kip1 antibody
|Database links|| |
|Protein function|| |
Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. .
|Protein tissue specificity|| |
Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney.
|Involvement in disease|| |
Multiple endocrine neoplasia 4 (MEN4) [MIM:610755]: Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the CDI family. A peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity.
|Protein post-translational modifications|| |
Phosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK1 and CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF. .; Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation. .; Subject to degradation in the lysosome. Interaction with SNX6 promotes lysosomal degradation (By similarity). .
|Protein cellular localization|| |
Nucleus. Cytoplasm. Endosome . Note=Nuclear and cytoplasmic in quiescent cells. AKT- or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6; this leads to lysosomal degradation (By similarity). .
AntibodyPlus can customize Anti-p27 KIP1 antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: